Researchers at the University of New South Wales and Boston University have developed an AI tool, CRANK-MS, that can predict the onset of Parkinson’s disease years before symptoms appear. The tool analyzes blood samples for unique combinations of metabolites that serve as early warning signs. Additionally, a study from the University of Western Australia demonstrates how data and AI can identify patients at high risk of cardiovascular complications after non-cardiac surgery. Medtech company HeraMED has partnered with Joondalup Obstetrics and Gynecology Group to deliver remote pregnancy monitoring solutions. Formus Labs has obtained FDA clearance for its AI-powered hip surgery planning software, Forums Hip.
A groundbreaking development has emerged from the collaborative efforts of the University of New South Wales and Boston University, as they have successfully created an AI tool capable of predicting the onset of Parkinson’s disease years before initial symptoms manifest. The tool, known as CRANK-MS (Classification and Ranking Analysis using Neural Networks to Generate Knowledge from Mass Spectrometry), employs machine learning techniques to analyze potential biomarkers present in a patient’s blood.
In a study recently published in the journal ACS Central Science, the research team examined blood samples from 39 individuals who later developed Parkinson’s disease within a span of up to 15 years. These samples were compared to those of 39 matched patients who did not develop the condition. By subjecting the participants’ blood metabolite data to the CRANK-MS algorithm, the researchers were able to identify unique combinations of metabolites that could serve as early warning signs for Parkinson’s disease.
AI Offers Promise in Preventing Post-Surgical Heart Complications
Another remarkable study has demonstrated the potential of data analysis and AI in preventing cardiovascular complications following non-cardiac surgeries. Led by a researcher from the University of Western Australia, the study utilized data from over 24,000 participants to determine whether machine learning and data analysis could accurately predict cardiovascular complications arising from non-heart surgeries, such as heart attacks and injury to the heart muscle before they occur.
The findings revealed that integrating machine learning techniques with routinely collected data before, during, and after surgery could significantly improve the identification of patients at the highest risk of experiencing these potentially fatal complications. Graham Hillis, a professor of medicine at UWA and head of cardiology at Royal Perth Hospital, emphasized the need for further refinement and integration of these methods into routine care to maximize their effectiveness.
HeraMED Partners with JOGG to Deliver Remote Pregnancy Monitoring Solutions
ASX-listed medtech company HeraMED has secured a partnership with Joondalup Obstetrics and Gynecology Group (JOGG), a reputable obstetric service provider based in Perth, Australia. This collaboration marks JOGG’s inaugural venture into remote pregnancy monitoring since its establishment in 2021. The agreement entails the acquisition of 120 licenses of HeraCARE, HeraMED’s digital maternity monitoring and management platform, along with HeraBEAT, their at-home fetal heart rate monitors.
Earlier in November of the previous year, HeraMED signed its first agreement with a private obstetrician practice for the deployment of HeraCARE. This recent partnership highlights the growing acceptance and adoption of HeraMED’s innovative remote pregnancy monitoring solutions within the medical community.
Formus Labs Receives FDA Clearance for Hip Surgery Planning Software
Formus Labs, a New Zealand-based medical technology company, has achieved a significant milestone with the granting of 510(k) clearance by the United States Food and Drug Administration (FDA) for their automated radiological image processing software designed for pre-operative planning of hip replacement surgeries. The software, named Formus Hip, harnesses the power of AI and computational biomechanics to calculate the optimal fit for a patient’s implant and generate fully interactive and actionable 3D surgical plans.
Following the FDA clearance, Formus Labs is now poised to make a definitive entry into the US market, aiming to provide healthcare professionals with advanced tools to enhance the accuracy and efficiency of hip replacement surgeries.
